G01N 2800/2878
Muscular dystrophy
G01N2800/2878 (Muscular dystrophy) appears on 65 US grants and 96 published applications in this corpus.
Search patents in G01N- Granted patents
- 65
- Published applications
- 96
- Assignees
- 93
- Inventors
- 243
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 0 | 2 |
| 2004 | 0 | 2 |
| 2005 | 2 | 4 |
| 2006 | 1 | 1 |
| 2007 | 2 | 0 |
| 2008 | 1 | 3 |
| 2009 | 1 | 2 |
| 2010 | 1 | 6 |
| 2011 | 0 | 5 |
| 2012 | 4 | 7 |
| 2013 | 3 | 3 |
| 2014 | 3 | 3 |
| 2015 | 3 | 9 |
| 2016 | 2 | 6 |
| 2017 | 4 | 6 |
| 2018 | 4 | 3 |
| 2019 | 4 | 2 |
| 2020 | 2 | 6 |
| 2021 | 2 | 5 |
| 2022 | 1 | 3 |
| 2023 | 2 | 1 |
| 2024 | 2 | 8 |
| 2025 | 2 | 3 |
| 2026 | 3 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- RAN proteins as biomarkers in CAG/CTG expansion disorders26 May 2026US 12,638,457 B2University of Florida Research Foundation, Inc.
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by an antisense nucleic acid molecule inhibiting the expression of double homeobox 4 (DUX4)12 May 2026US 12,624,396 B2Fred Hutchinson Cancer Center
- Anti-TDP-43 binding molecules and uses thereof14 Apr 2026US 12,600,766 B2AC Immune SA
- Compositions for the treatment of sarcopenia or disuse atrophy16 Dec 2025US 12,496,328 B2Association Institut De Myologie
- Discriminating Parkinson's disease from multiple system atrophy using alpha-synuclein PMCA1 Apr 2025US 12,265,089 B2Amprion, Inc.
- Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)27 Aug 2026US 2026/0250769 A1Fred Hutchinson Cancer Center
- Novel biomarker for determining disease activity or prognosis of facioscapulohumeral muscular dystrophy4 Jun 2026US 2026/0153519 A1Avidity Biosciences, Inc.
- Discriminating Parkinson's Disease from Multiple System Atrophy Using Alpha- Synuclein PMCA29 Jan 2026US 2026/0029413 A1Board of Regents, The University of Texas System
- Methods of treating muscular dystrophy1 Jan 2026US 2026/0002175 A1Sarepta Therapeutics, Inc.
- Discriminating Parkinson's Disease from Multiple System Atrophy Using Alpha-Synuclein PMCA25 Dec 2025US 2025/0389732 A1Amprion, Inc.
Most cited
By later US patents
- Methods and compositions for targeting compounds to muscle70US 6,329,501 B1Auburn University · 2001
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL32US 10,865,445 B2Fred Hutchinson Cancer Research Center · 2020
- Nucleic acid encoding dystrophin-associated protein32US 5,449,616 AUniversity of Iowa Research Foundation · 1995
- Probes for and nucleic acid encoding the muscular dystrophy protein, dystrophin30US 5,621,091 AChildren's Medical Center Corporation · 1997
- Muscular dystrophy protein, dystrophin13US 5,239,060 AChildren's Medical Center Corporation · 1993